Previous 10 | Next 10 |
– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – BOSTON, July 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ...
The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...
Thinly traded micro cap resTORbio ( TORC +1.5% ) is up on below-average volume in response to the release of more data from a Phase 2b clinical trial evaluating lead candidate RTB101 in patients at least 65 years old at high risk of respiratory tract infections (RTIs). The resu...
RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory confirmation) by 66.4% (p=0.003) as compared to placebo among Phase 2b participants 65 years of age an...
resTORbio (NASDAQ: TORC ): Q1 GAAP EPS of -$0.38 misses by $0.02 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson’s disease (PD) Completed ...
BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the appointment of Lloyd Klickstein, M.D., Ph.D., ...
BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1), in an oral presentation ...
The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...
BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). The two PROTECTOR Phase 3 trials are ...
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...